Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ADMA Biologics, Inc.

https://www.admabiologics.com/

Latest From ADMA Biologics, Inc.

Finance Watch: Biopharma Stocks See Big Post-IPO Jumps

Public Company Edition: Five out of six drug developers and a CRO have seen their values spike immediately after going public this month. Also, Moderna floats a $500m offering, Revance proposes a $20m note sale, and Nestle invests another $200m in Aimmune.

Financing Business Strategies

Keeping Track: US Approvals For Xpovio And Xembify Highlight Short Holiday Week

The latest drug development news and highlights from our US FDA Performance Tracker.

Approvals Drug Review

Finance Watch: Q1 Numbers Suggest A Brisk VC Deal Pace For Cell And Gene Therapies In 2019

An Alliance for Regenerative Medicine (ARM) report shows big Q1 numbers for venture capital and partnership deals. Also, mid-May VC deals surge globally across therapeutic areas, Biogen pushes back against a bargain-hunting investor and recent public company financings.

Financing Regenerative Medicine

Keeping Track: Resubmissions For Tlando And Twirla NDAs, And A BTD For Pomalyst

The latest drug development news and highlights from our US FDA Performance Tracker.

Drug Review Regulation
See All

Company Information

  • Industry
  • Pharmaceuticals
UsernamePublicRestriction

Register